Report : Europe Plant-based Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Vaccine Type (Bacterial Vaccines, Viral Vaccines, Parasite Vaccines, and Others), Source (Tobacco Plant, Maize, Potato, and Others), and Application (Influenza, Zika Virus, Ebola Virus, Poultry Disease, and Others)
Tobacco Plant Segment to Dominate Europe Plant-based Vaccines Market during 2020–2028
According to a new market research study on “Europe Plant-based Vaccines Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Vaccine Type, Source, and Application” is expected to reach US$ 705.15 million by 2028 from 306.40 US$ million in 2021. The market is estimated to grow at a CAGR of 13.1% from 2021 to 2028. The report provides trends prevailing in the Europe plant-based vaccines market along with the drivers and restraints pertaining to the market growth. Surge in plant-based vaccines production is the major factor driving the growth of the Europe plant-based vaccines market. However, issues associated with manufacturing plant-based vaccines facing high risk of contamination and environmental risks for hinders the growth of Europe plant-based vaccines market.
Europe plant-based vaccines market is segmented into vaccine type, source, application, and country. Based on vaccine type, the Europe plant-based vaccines market is segmented into bacterial vaccines, viral vaccines, parasite vaccines, plant-derived virus-like particles, and others. The bacterial vaccines segment held the largest share of the market in 2021. Based on source, the Europe plant-based vaccines market is segmented into tobacco plant, maize, potato, and others. The tobacco plant segment held the largest share of the market in 2021. Based on application, the Europe plant-based vaccines market is segmented into influenza, zika virus, Ebola virus, poultry disease, COVID-19, and others. The influenza segment held the largest share of the market in 2021. Based on country, the Europe plant-based vaccines market is segmented into France, Germany, Italy, Spain, the UK, and rest of Europe. Germany held the largest market share in 2021.
Reliable and timely COVID-19 testing is an integral part of the monitoring, prevention, touch recording, and control of infections, and clinical management of COVID-19. The European Center for Disease Prevention and Control (ECDC) has proposed an analytical testing strategy for the EU with concrete guidelines on the level of dissemination of viruses in the population, considering the available public health tools and testing ability. A survey undertaken by the European Commission Health Protection Committee in September 2020 investigated the activities of Member States in the use of rapid antigen tests. Fifteen EU member states responded to the survey, out of them five states are using rapid antigen tests on certain aspects of the response to the COVID-19 pandemic. Nine of the fifteen countries are currently conducting clinical validation trials or pilots to evaluate the clinical/diagnostic efficiency and future use of rapid antigen tests, and 2 member states are not considering the use of rapid antigen tests. According to the report, some countries use the tests as part of their research policy for early detection of infection, contact tracking and/or rapid isolation, and quarantine of identified cases and their contacts. Other countries use rapid antigen tests explicitly to ensure laboratory testing in remote areas where the RT-PCR gold standard is not available or timely enough.
British American Tobacco p.l.c.; Creative Biolabs, Inc.; Leaf Expression Systems Ltd.; LenioBio; Lumen Bioscience, Inc.; and ZYUS Life Sciences Inc. are among the leading companies in the Europe plant-based vaccines market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, LenioBio GmbH has awarded with a grant of €2.37 million to accelerate the scale-up of its proprietary protein expression platform ALiCE.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org